<p>纽约，2026 年 1 月 20 日（全球新闻稿）——Psyence Biomedical Ltd.（纳斯达克：PBM）（“Psyence BioMed” 或 “公司”）今天宣布，决定推迟之前宣布的反向股票拆分的生效日期。</p>
<p>如之前所披露，公司董事会批准了 1 比 6.25 的反向股票拆分，计划于 2026 年 1 月 20 日市场开盘时生效。经过进一步的内部考虑，公司决定将反向股票拆分的生效日期推迟至更晚的时间。</p>
<p>公司将在确定反向股票拆分的新生效日期之前发布后续新闻稿，并向纳斯达克提交任何必要的通知。在此之前，公司普通股将继续以未调整拆分的方式在纳斯达克资本市场交易，股票代码为 “PBM”，并保持当前的 CUSIP 74449F308。</p>
<p>董事会保留决定反向股票拆分是否以及何时生效的权力。</p>
<p><strong>关于 Psyence BioMed</strong></p>
<p>Psyence Biomedical Ltd.（纳斯达克：PBM）是少数几家专注于迷幻药物治疗的多资产、垂直整合的生物制药公司之一。它是第一家专注于开发自然来源（非合成）的裸盖菇素和伊波卡因基础的迷幻药物的生命科学生物技术公司，并在纳斯达克上市。我们致力于解决未满足的心理健康需求。我们承诺采用基于证据的方法，开发安全、有效且获得 FDA 批准的自然来源迷幻治疗，针对广泛的心理健康障碍。</p>
<p><strong>Psyence Biomedical Ltd. 联系信息</strong></p>
<p>电子邮件：ir@psyencebiomed.com</p>
<p>媒体咨询：media@psyencebiomed.com</p>
<p>一般信息：info@psyencebiomed.com</p>
<p><strong>投资者联系：</strong></p>
<p>Michael Kydd</p>
<p>投资者关系顾问</p>
<p>michael@psyencebiomed.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本通讯包含 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”。此类声明包括但不限于关于未来财务和运营结果、我们的计划、目标、期望和意图的声明，涉及未来的运营、产品和服务；以及其他用 “可能导致”、“预期”、“将继续”、“预计”、“估计”、“相信”、“打算”、“计划”、“预测”、“展望” 或类似含义的词语标识的声明。</p>
<p>本通讯中的前瞻性声明包括关于之前宣布的反向股票拆分的潜在未来有效性、该有效性的时间（如有）以及公司决定是否以及何时进行反向股票拆分的意图。这些声明基于当前的假设和期望，包括公司可能选择为反向股票拆分设定新的生效日期，以及公司将继续满足纳斯达克的持续上市标准。这些假设可能被证明是错误的。不能保证公司能够保持符合纳斯达克的持续上市要求。存在许多风险和不确定性，可能导致实际结果或表现与这些前瞻性声明所表达或暗示的结果有重大不同。</p>
<p>这些风险和不确定性包括但不限于：（i）在决定是否实施或实施反向股票拆分时的延迟或挑战；（ii）公司维持符合纳斯达克持续上市标准的能力；（iii）无论反向股票拆分是否最终实施，公司股价可能的波动；（iv）监管、竞争和经济环境的变化；（v）与公司发展计划和临床试验相关的风险；以及（vi）与公司对股票合并的公司授权相关的风险，包括对授权股票合并的股东决议的有效性、解释或充分性的质疑或诉讼的可能性。上述因素的清单并不详尽。您应仔细考虑上述因素以及公司最终招股说明书（文件编号：333-298285）中 “风险因素” 部分描述的其他风险和不确定性，该招股说明书于 2025 年 11 月 3 日提交给证券交易委员会（“SEC”），以及 Psyence BioMed 不时向 SEC 提交的其他文件。</p>
<p>这些文件识别并解决了可能导致实际事件和结果与前瞻性声明中包含的内容有重大不同的其他重要风险和不确定性。实际结果和未来事件可能与这些声明中预期的有重大不同。本通讯中的任何内容均不应被视为任何人对前瞻性声明所述内容将会实现的陈述，或对这些前瞻性声明所设想的任何结果将会实现的陈述。您不应对前瞻性声明过度依赖，这些声明仅在作出时有效。除法律要求外，Psyence BioMed 不打算更新这些前瞻性声明。</p>
<p>公司不对其拟议产品做出任何医疗、治疗或健康益处的声明。美国食品药品监督管理局、加拿大卫生部或其他类似监管机构尚未评估关于迷幻蘑菇、迷幻蘑菇类似物或其他迷幻化合物或营养保健产品的声明。这些产品的有效性尚未通过授权的临床研究确认。无法保证使用迷幻蘑菇、迷幻蘑菇类似物或其他迷幻化合物或营养保健品能够诊断、治疗、治愈或预防任何疾病或状况。需要进行严格的科学研究和临床试验。公司的产品候选者属于研究性质，尚未获得任何监管机构的批准用于治疗任何疾病或状况，临床结果（如有）可能无法代表未来的结果。任何关于潜在产品的质量、一致性、有效性和安全性的引用并不意味着公司已在临床试验中验证这些内容，或公司将完成这些试验。如果公司无法获得商业化其业务所需的批准或研究，可能会对公司的业绩和运营产生重大不利影响。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9EWXlPQ00zTXpjd01EZzRJekl5T0RVNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9EWXlPQ00zTXpjd01EZzRJekl5T0RVNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWE2NWY3YzUtMjgyYy00NTgwLTg5N2QtY2FhYTczMmNmMjBkLTEyOTc0NjctMjAyNi0wMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWE2NWY3YzUtMjgyYy00NTgwLTg5N2QtY2FhYTczMmNmMjBkLTEyOTc0NjctMjAyNi0wMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

<p>Psyence Biomedical Ltd. 已推迟其之前宣布的 1 比 6.25 的反向股票拆分的生效日期，原定于 2026 年 1 月 20 日。此决定是在进一步内部考虑后做出的，公司将发布新的新闻稿，公布修订后的生效日期。在此之前，股票将继续在纳斯达克以 "PBM" 的代码交易，且不作调整。董事会保留拆分时机的决定权</p>

<p>NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock.</p>
<div class="lb-trans"><p>纽约，2026 年 1 月 20 日（全球新闻稿）——Psyence Biomedical Ltd.（纳斯达克：PBM）（“Psyence BioMed” 或 “公司”）今天宣布，决定推迟之前宣布的反向股票拆分的生效日期。</p>
</div><p>As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026. Following further internal consideration, the Company has elected to delay the effectiveness of the reverse stock split to a later date.</p>
<div class="lb-trans"><p>如之前所披露，公司董事会批准了 1 比 6.25 的反向股票拆分，计划于 2026 年 1 月 20 日市场开盘时生效。经过进一步的内部考虑，公司决定将反向股票拆分的生效日期推迟至更晚的时间。</p>
</div><p>The Company will issue a subsequent press release and file any required notifications with Nasdaq prior to establishing a new effective date for the reverse stock split. Until such time, the Company’s common stock will continue to trade on the Nasdaq Capital Market on a split-unadjusted basis under the ticker symbol &#34;PBM&#34; and under its current CUSIP 74449F308.</p>
<div class="lb-trans"><p>公司将在确定反向股票拆分的新生效日期之前发布后续新闻稿，并向纳斯达克提交任何必要的通知。在此之前，公司普通股将继续以未调整拆分的方式在纳斯达克资本市场交易，股票代码为 “PBM”，并保持当前的 CUSIP 74449F308。</p>
</div><p>The Board of Directors retains the discretion to determine if and when the reverse stock split will be effected.</p>
<div class="lb-trans"><p>董事会保留决定反向股票拆分是否以及何时生效的权力。</p>
</div><p><strong>About Psyence BioMed</strong></p>
<div class="lb-trans"><p><strong>关于 Psyence BioMed</strong></p>
</div><p>Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.</p>
<div class="lb-trans"><p>Psyence Biomedical Ltd.（纳斯达克：PBM）是少数几家专注于迷幻药物治疗的多资产、垂直整合的生物制药公司之一。它是第一家专注于开发自然来源（非合成）的裸盖菇素和伊波卡因基础的迷幻药物的生命科学生物技术公司，并在纳斯达克上市。我们致力于解决未满足的心理健康需求。我们承诺采用基于证据的方法，开发安全、有效且获得 FDA 批准的自然来源迷幻治疗，针对广泛的心理健康障碍。</p>
</div><p><strong>Contact Information for Psyence Biomedical Ltd.</strong></p>
<div class="lb-trans"><p><strong>Psyence Biomedical Ltd. 联系信息</strong></p>
</div><p>Email: ir@psyencebiomed.com</p>
<div class="lb-trans"><p>电子邮件：ir@psyencebiomed.com</p>
</div><p>Media Inquiries: media@psyencebiomed.com</p>
<div class="lb-trans"><p>媒体咨询：media@psyencebiomed.com</p>
</div><p>General Information: info@psyencebiomed.com</p>
<div class="lb-trans"><p>一般信息：info@psyencebiomed.com</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Michael Kydd</p>
<div class="lb-trans"><p>Michael Kydd</p>
</div><p>Investor Relations Advisor</p>
<div class="lb-trans"><p>投资者关系顾问</p>
</div><p>michael@psyencebiomed.com</p>
<div class="lb-trans"><p>michael@psyencebiomed.com</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.</p>
<div class="lb-trans"><p>本通讯包含 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”。此类声明包括但不限于关于未来财务和运营结果、我们的计划、目标、期望和意图的声明，涉及未来的运营、产品和服务；以及其他用 “可能导致”、“预期”、“将继续”、“预计”、“估计”、“相信”、“打算”、“计划”、“预测”、“展望” 或类似含义的词语标识的声明。</p>
</div><p>Forward-looking statements in this communication include statements regarding the potential future effectiveness of the previously announced reverse stock split, the timing (if any) of such effectiveness, and the Company’s intention to determine whether and when to proceed with the reverse stock split. These statements are based on current assumptions and expectations, including that the Company may elect to establish a new effective date for the reverse stock split, and that the Company will continue to meet Nasdaq’s ongoing listing standards. These assumptions may prove incorrect. There can be no assurance that the Company will be able to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本通讯中的前瞻性声明包括关于之前宣布的反向股票拆分的潜在未来有效性、该有效性的时间（如有）以及公司决定是否以及何时进行反向股票拆分的意图。这些声明基于当前的假设和期望，包括公司可能选择为反向股票拆分设定新的生效日期，以及公司将继续满足纳斯达克的持续上市标准。这些假设可能被证明是错误的。不能保证公司能够保持符合纳斯达克的持续上市要求。存在许多风险和不确定性，可能导致实际结果或表现与这些前瞻性声明所表达或暗示的结果有重大不同。</p>
</div><p>These risks and uncertainties include, among others: (i) delays or challenges in determining whether to effect or in effecting the reverse stock split; (ii) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (iii) potential volatility in the Company’s share price whether or not a reverse stock split is ultimately effected; (iv) changes in the regulatory, competitive, and economic landscape; (v) risks associated with the Company’s development plans and clinical trials; and (vi) risks related to the Company’s corporate authorizations for the share consolidation, including the possibility of claims or proceedings challenging the validity, interpretation or sufficiency of the shareholder resolutions authorizing the share consolidation. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.</p>
<div class="lb-trans"><p>这些风险和不确定性包括但不限于：（i）在决定是否实施或实施反向股票拆分时的延迟或挑战；（ii）公司维持符合纳斯达克持续上市标准的能力；（iii）无论反向股票拆分是否最终实施，公司股价可能的波动；（iv）监管、竞争和经济环境的变化；（v）与公司发展计划和临床试验相关的风险；以及（vi）与公司对股票合并的公司授权相关的风险，包括对授权股票合并的股东决议的有效性、解释或充分性的质疑或诉讼的可能性。上述因素的清单并不详尽。您应仔细考虑上述因素以及公司最终招股说明书（文件编号：333-298285）中 “风险因素” 部分描述的其他风险和不确定性，该招股说明书于 2025 年 11 月 3 日提交给证券交易委员会（“SEC”），以及 Psyence BioMed 不时向 SEC 提交的其他文件。</p>
</div><p>These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.</p>
<div class="lb-trans"><p>这些文件识别并解决了可能导致实际事件和结果与前瞻性声明中包含的内容有重大不同的其他重要风险和不确定性。实际结果和未来事件可能与这些声明中预期的有重大不同。本通讯中的任何内容均不应被视为任何人对前瞻性声明所述内容将会实现的陈述，或对这些前瞻性声明所设想的任何结果将会实现的陈述。您不应对前瞻性声明过度依赖，这些声明仅在作出时有效。除法律要求外，Psyence BioMed 不打算更新这些前瞻性声明。</p>
</div><p>The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company’s product candidates are investigational and have not been approved by any regulatory authority for use in the treatment of any disease or condition, and clinical results (if any) may not be indicative of future results. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.</p>
<div class="lb-trans"><p>公司不对其拟议产品做出任何医疗、治疗或健康益处的声明。美国食品药品监督管理局、加拿大卫生部或其他类似监管机构尚未评估关于迷幻蘑菇、迷幻蘑菇类似物或其他迷幻化合物或营养保健产品的声明。这些产品的有效性尚未通过授权的临床研究确认。无法保证使用迷幻蘑菇、迷幻蘑菇类似物或其他迷幻化合物或营养保健品能够诊断、治疗、治愈或预防任何疾病或状况。需要进行严格的科学研究和临床试验。公司的产品候选者属于研究性质，尚未获得任何监管机构的批准用于治疗任何疾病或状况，临床结果（如有）可能无法代表未来的结果。任何关于潜在产品的质量、一致性、有效性和安全性的引用并不意味着公司已在临床试验中验证这些内容，或公司将完成这些试验。如果公司无法获得商业化其业务所需的批准或研究，可能会对公司的业绩和运营产生重大不利影响。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9EWXlPQ00zTXpjd01EZzRJekl5T0RVNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyODYyOCM3MzcwMDg4IzIyODU5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWE2NWY3YzUtMjgyYy00NTgwLTg5N2QtY2FhYTczMmNmMjBkLTEyOTc0NjctMjAyNi0wMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png" alt="" original-src="https://ml.globenewswire.com/media/MWE2NWY3YzUtMjgyYy00NTgwLTg5N2QtY2FhYTczMmNmMjBkLTEyOTc0NjctMjAyNi0wMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date | PBM Stock News

StockTitan

美国制药 ETF - iShares

医疗业 ETF - Vanguard

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

Psyence Biomedical

标普生物技术 ETF - SPDR

Psyence BioMed 宣布推迟之前宣布的反向股票拆分生效日期 | PBM 股票新闻